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control (ES = 0.09), whereas controls revealed no significant 
improvements in these measures. Further improvements in 
the OT group were found for ‘perceived control always’ (ACT, 
p = 0.006), no impairment (ACT, p = 0.02), reduction of sick-
ness days (p = 0.002) and number of medications needed 
(p = 0.001).  Conclusions: Substantial beneficial effects of 
omalizumab, similar to those observed in controlled trials 
and after marketing studies, were confirmed, particularly 
with regard to the reduction of asthma attacks, persistence 
of symptoms, asthma control and reduction of concomitant 
asthma medications. This study provides a tougher test and 
generalizable evidence for the effectiveness of omalizumab 
in routine care.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 A series of controlled clinical trials has established the 
superior efficacy of omalizumab in patients with severe 
allergic asthma (SAA) compared to placebo and standard 
treatment  [1, 2] . Consequently, omalizumab (Xolair; No-
vartis AG, Basel, Switzerland) was listed with the highest 
evidence for the effective treatment of uncontrolled al-
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 Abstract 
 Background: It is unclear how far the superior efficacy of 
omalizumab, established in randomized controlled clinical 
trials of patients with severe allergic asthma (SAA), translates 
into routine practice and when compared to matched con-
trols.  Methods: New-onset omalizumab-treated (OT) pa-
tients with SAA (n = 53) were compared to a matched control 
group of usual-care (UC) patients (n = 53). Treatment and 
procedures were naturalistic. Subsequent to a baseline as-
sessment, patients were followed up over at least 6 months 
with at least two follow-up assessments. Primary clinical out-
comes were the number of asthma attacks, persistence of 
asthma symptoms and degree of control [asthma control 
test (ACT), Global Initiative for Asthma]. Secondary outcome 
criteria were quality of life (Euro-Qol 5D) and number of 
medications. For each outcome we compared within-group 
effects from baseline to 6-month follow-up as well as be-
tween-group effects.  Results: OT patients showed signifi-
cant improvements in number [effect size (ES) = 0.03] and 
frequency (ES = 0.04) of asthma attacks as well as asthma 
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lergic asthma (AA) on treatment step 5 in the Global Ini-
tiative for Asthma (GINA, 2007) and in the Asthma 
Guidelines of the German Respiratory Society  [3] . Fairly 
consistently superior findings were found: a lower inci-
dence and frequency of exacerbations, a reduction of in-
haled corticosteroids (ICS), a less frequent need for rescue 
medication and a reduction of emergency visits, as well 
as a significant improvement in quality of life  [4–7] . 
Moreover, its safety and tolerability have been previously 
described  [8] .
 There is evidence that these effects, established in con-
trolled clinical trials, also translate into clinical practice. 
Molimard et al.  [9]  reported long-term follow-up data of 
147 patients who had had omalizumab prescribed be-
tween 2003 and 2006. Compared with the year before 
treatment, the percentage of patients without exacerba-
tions doubled, emergency visits (–69%) and hospitaliza-
tions (–53%) decreased, 25.6% of patients stopped using 
or lowered the dose of ICS, and 48.1% reduced or discon-
tinued maintenance on ICS. Korn et al. [10] , in a post-
marketing surveillance trial of 280 patients with severe 
persistent allergic asthma, described effects in terms of 
daily symptoms (–76%), exacerbations (–82%, hospital-
izations (–78%), control status and quality of life [Mini 
Asthma Quality of Life Questionnaire (AQLQ) increase: 
2.9–4.5]. Bousquet et al.  [1] performed a pooled analysis 
of data from the INNOVATE study, pointing out that pa-
tients being treated with omalizumab showed a signifi-
cant decrease in asthma exacerbations (40–50% decrease 
vs. control), fewer severe exacerbations (40–70% vs. con-
trol) and significantly fewer emergency visits (30–60% 
compared with controls)  [11] . Ayres et al.  [4]  compared 
206 patients with omalizumab therapy and 106 patients 
with standard treatment. They reported a significant re-
duction of asthma deterioration-related incidents (course 
of systemic corticosteroids or antibiotics for  6 2 days,  6 2 
missed school/work days) in patients treated with omali-
zumab (reduction 49.6%), and significantly fewer asthma 
exacerbations (reduction 60.8%). Moreover, omalizumab 
treatment (OT) improved lung function parameter 
(FEV 1 ) more significantly than standard treatment. 
 To summarize, as controlled studies, these naturalistic 
and real-life studies have typically found similar promis-
ing effects. However, considerable caution is warranted 
given the weaknesses of uncontrolled naturalistic obser-
vational studies. Further, it should be noted that none of 
the available real-life studies had implemented a control 
group with standard treatment. It is unknown what the 
natural course of patients would have been in the same 
time period under conventional routine treatment.
 To avoid most of these weaknesses, we present a more 
sophisticated approach to estimate the effects of omali-
zumab under real-life conditions. To eliminate system-
atic selection effects as far as possible, sampling of pa-
tients is based on a nationwide representative patient 
population, recruited as part of a previous clinical-epide-
miological study  [12] . From the same patient population 
we also selected matched controls without omalizumab 
treatment. This allowed us to estimate the reduction in 
each group, as well as to compare the effects in both 
groups. Our aims were:
 (1) To describe in a prospective naturalistic matched-
control group design the effects of add-on omalizu-
mab treatment over a period of 6–8 months in 106 
subjects with uncontrolled SAA. One group compris-
ing 53 patients received OT and a group of 53 care-
fully matched ‘usual care’ (UC) controls went without 
omalizumab. Outcome variables were: mean number 
of asthma attacks, frequency of asthma symptoms, 
degree of asthma control (primary) and quality of life 
(secondary). 
 (2) To compare, over a period of 6–8 months, the effects 
of treatment with omalizumab to the controls to test 
whether OT outcomes were superior to UC.  
 Materials and Methods 
 This prospective-longitudinal cohort study was part of the Se-
vere Asthma Patients Needs Study (sap-NEEDs; Severe Allergic 
Asthma: Prevalence and Current Treatment Needs), described 
elsewhere in detail  [12] . Briefly, sap-NEEDs was a 3-stage, nation-
wide, cross-sectional (stages 1 and 2) and prospective (stage 3) 
clinical-epidemiological study in a nationally representative sam-
ple of 756 pulmonary specialists and their patients (stage 1). In 
stage 2 of sap-NEEDs, a random sample of 572 patients (response 
rate: 68%) recruited from a random subset of 146/756 settings un-
derwent a comprehensive clinical assessment supplemented by a 
patient questionnaire. This contained questions regarding patient 
characteristics, symptomatology, treatment and established 
scales including the AQLQ  [13] , the generic Euro-Qol 5D (EQ5D) 
questionnaire   [14] , the Asthma Control Test (ACT)  [15] and men-
tal health status scales (CIDI-SF)  [16] . From this stage-2 database 
(total of 572 patients with allergic asthma), patients diagnosed 
with a stage III and IV asthma severity according to NVL (‘Natio-
nale Versorgungsleitlinie Asthma’, i.e. National Guidelines for 
Diagnosis and Treatment of Asthma, n = 339) were eligible and 
targeted as potential participants for the prospective-longitudinal 
naturalistic cohort study dealt with in this paper. At the time the 
study was conducted, the NVL guidelines were identical to GINA 
in terms of grading the severity of asthma. However, it did not 
include the therapy staging of GINA; this was adopted only after 
the study had been completed. In order to reflect this change and 
to be consistent with international standards, we decided to use 
GINA criteria.
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 Design and Patient Groups 
 The design of the cohort is displayed in  figure 1 . The selection 
of patients for this longitudinal component was based on a com-
plete listing of all patients with SAA together with a clinical char-
acterization made by their treating physicians, obtained from 
stage 2 of the study  [12] . The patients sample was based on find-
ings from the stage 2 questionnaire that asked the treating physi-
cian what type of treatment (including omalizumab) he/she ei-
ther currently administered to this patient or considered admin-
istering in the near future. This applied for 81 patients. If these 
patients met the inclusion and exclusion criteria, the physician 
was requested to ask for informed consent for the study proce-
n = 2 Treatment stop due to side effects (T1–T2)
n = 1 Lost to follow-up after T2 (unknown reason)
n = 17 No participation due to assessment burden
n = 4   With prior omalizumab treatment
n = 2   Psychiatric (1), somatic (1) comorbidities
n = 1   Rediagnosed (no SAA)
n = 1   Moved abroad
n = 1 Lost prior to T1 (unknown reason)
n = 2 Not included to match sample size
n = 81
Potentially eligible
patients with SAA
(potential OT group)
n = 56
Patients with
treatment included (T1)
(OT group realized)
n = 53
Patients with SAA and
omalizumab (T3)
(OT group completers)
n = 56
Matched patients with
‘usual care’ (T1)
(UC group realized)
n = 53
Matched patients with
‘usual care’ (T3)
(UC group completers)
Sap-NEEDs study (stage 2)
572 asthma patients listed by 146 settings (routine respiratory specialist care)
n = 339
Potentially eligible patients for longitudinal study
(n = 154 asthma severity stage III, n = 185 asthma severity stage IV according to NVL)
 Fig. 1. Study design. 
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dures (potential OT group). The UC group selected by the study 
center was also based on the available stage-2 data, by matching 
patients that had biosocial and clinical characteristics similar to 
those of patients in the OT group (same inclusion and exclusion 
criteria). 
 Inclusion and Exclusion Criteria 
 All patients had to meet the diagnostic study criteria for un-
controlled SAA (according to GINA). General inclusion criteria 
were: written informed consent, age 16–75 years, severe persistent 
allergic asthma, positive skin test or in vitro reactivity to peren-
nial aeroallergen, reduced lung function [(FEV 1 )  ! 80%, peak ex-
piratory flow 60–80% or daytime variability  1 30%], frequent day-
time symptoms and severe exacerbations. Exclusion criteria were: 
prior OT, other severe somatic and psychiatric conditions that 
required continuous medication treatment or frequent consulta-
tions and conditions that would make regular assessments of the 
patients impossible due to logistical or ethical reasons (e.g. lan-
guage problems, acute pain and suffering).
 Omalizumab Treatment Group 
 Of the 81 potentially eligible patients approached, 17/81 de-
clined participation, mostly because of the associated assessment 
burden, and 8 (8.6%) dropped out because they did not meet the 
study criteria. Four had had previous OT, 1 had end-stage cancer 
and another had severe depression (a suicide attempt). One pa-
tient did not meet the diagnostic criteria of SAA and 1 was about 
to move abroad. So 56 patients were enrolled in the study; 3 
stopped taking omalizumab after 2–5 weeks of observation (dis-
continued by the treating physician because of adverse reactions 
or side effects). So the OT group finally comprised 53 patients. 
The dosage of omalizumab was determined according to the 
treatment guidelines, based upon a patient’s body weight and IgE 
levels.
 ‘Usual Care’ Control Group 
 The same inclusion criteria applied for this group, except that 
for these patients no OT was considered, i.e. ‘usual care’ refers to 
step 1–5 of the GINA scheme but without OT. We matched 56 
control subjects to the original 56 omalizumab patients (see be-
low). Matching started with biosocial characteristics and includ-
ed clinical characteristics (e.g. smoking status, FEV 1 , number of 
allergies, duration of prior treatment and exacerbations over the 
past 12 months) to optimize the match ( table  1 ). All patients 
agreed to participate. One dropped out before the first follow-up 
assessment. To obtain equal group sizes, we restricted the analy-
ses to 53 patients who were matched to the patients in the OT 
group (this exclusion had no effects on the results).
 Procedure 
 As shown in  figure 1 , patients were followed up by indepen-
dent clinical monitors with 3 assessments (T1–T3) over at least 6 
months. The physician again completed a standardized clinical 
appraisal for each patient. All patients completed an exam prior 
to entering the study consisting of a standardized clinical assess-
ment and a self-report questionnaire. Controls continued their 
UC treatment without omalizumab. The OT group started their 
treatment subsequently. Data are presented for both groups with 
their baseline (T1), intermediate (T2 at 2–3 months) and final 
follow-up (T3 at 6–8 months) assessments. Out of 106 patients, 
104 completed all the assessments. Two omalizumab patients 
stopped their medication between T1 and T2 due to clinical rea-
sons (side effects and tolerability). None of the 53 controls 
dropped out. 
 Baseline and Follow-Up Assessment 
 The baseline and follow-up assessments consisted of a stan-
dardized, interviewer-based assessment of the following vari-
ables, which served as outcome measures: number of patients with 
asthma attacks, mean number of asthma attacks and number of 
patients with daily and frequent day/night symptoms during the 
past 4 weeks were assessed with the Asthma Symptom List and 
the Asthma Trigger Inventory  [17] . The frequency of asthma 
symptoms during the past 4 weeks was assessed with a corre-
sponding ad hoc item which could be answered by the patient as 
‘daily (permanently)’, ‘daily (frequently)’, ‘not daily, but x times 
per week’ or ‘none’. In this paper, patients who reported ‘daily 
(permanently)’ or ‘daily (frequently)’ were pooled as having ‘dai-
ly symptoms’. Asthma control was assessed with the ACT  [18] . 
Here, a patient was classified as having ‘partially controlled’ asth-
ma when he/she scored 20–24 (out of 25) or ‘no control’ when he/
she scored  ̂  19.
 Quality of life was assessed by the EQ-5D using the proportion 
of patients with ‘any problems in usual activities’ and ‘any dis-
comfort due to symptoms’ as core indicators  [14] . The clinician 
also rated the following variables: exacerbations during the past 4 
weeks, lung function (current peak expiratory flow), number of 
emergency visits (hospitalizations, ER visits or need of ventila-
tion) and,  performed a final appraisal of efficacy and tolerability 
upon conclusion of T3.  
 Analyses 
 Baseline characteristics of the OT and UC group were com-
pared by a   2 test for nominal data and a Student t test for interval 
data. The UC group was matched by propensity score  [19] . The 
propensity score was the probability to be in the OT given the 
matching variables. Each subject in the OT group was matched to 
the subject with the closest propensity score from the UC sample. 
Power analyses were conducted for estimating the statistical pow-
er for the applied test procedures in our sample  [20] . Changes in 
the outcome variables from T1 to T2 and T3 were reported as 
change in percentage for nominal data and change in the mean 
for interval data. The within-group changes were assessed by 
paired t tests and a paired sample proportion test. The standard-
ized change (effect size) from T1 to T3 was estimated by the mean 
difference divided by its pooled standard deviations (SDs). The 
effect size provides a comparison of changes for different outcome 
variables. Regarding the primary aims and the design of the sap-
NEEDs project, we analyzed the in-group differences for the 
change of T1–T3 by a bootstrap test for ratio, applying 5,000 boot-
strap replications. The treatment effect at T2 is reported as ratio 
with the reference group UC. Missing observations in outcome 
variables due to item nonresponse were imputed by the last-ob-
servation-carried-forward approach. A sensitivity analysis con-
sidering only complete cases did not reveal different study results. 
Standard errors were robustly estimated. Statistical significance 
is based on p  ! 0.05. All statistical analyses were performed using 
STATA 11.
 The local ethics committee reviewed and approved the study 
protocol (9 May, 2008, ref. EK 43032008).
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 Results 
 Patients 
 A summary of the baseline characteristics of both 
groups is reported in  table 1 . Overall, the groups are rela-
tively well balanced regarding most variables, revealing 
significant differences only with regard to the higher rate 
of systemic corticosterioids in the OT group (66 vs. 39.6%, 
p = 0.0006). Half of the sample was female; mean age was 
48.3 and 51.9 years, respectively. They did not differ with 
regard to duration of illness (19.7/24.1 years, p = 0.231), 
duration of prior treatments (20.3/21.8 years, p = 0.661), 
and the frequency of concomitant asthma medications 
(96.2/90.6%, p = 0.241).
Table 1.  Baseline characteristics of the study sample of 106 patients
OT group UC group p valuea
Number of patients 53 53
Mean age 8 SD (range), years 48.3813.7 (16–72) 51.9815.9 (19–74) 0.212
Sex, %
Male 50.9 50.9 1
Female 49.1 49.1
Professional status, %
Employed 52.2 40.4 0.371
Retired 34.8 51.9
Seeking work 8.7 5.8
Homemaker 4.4 1.9
Mean years of schooling 8 SD 11.483.1 10.882.5 0.318
Smoking status, %
Ex-smoker 38.3 32.7 0.836
Current smoker 6.4 7.7
Mean serum total IgE 8 SD, I.E./ml 605.18793.5 374.28539.2 0.141
Mean FEV1 %b 8 SD 67823 62819 0.262
Mean peak flow reversibility 8 SD 24.1842.0 26.9848.0 0.891
Mean vital capacity %b 8 SD 85822 86823 0.808
Mean duration of allergic asthma 8 SD, years 19.7814.6 24.1817.8 0.231
Mean duration of prior treatment 8 SD, years 20.3814.8 21.8815.6 0.661
Mean number of exacerbations in the last
12 months 8 SD 3.182.6 4.887.9 0.266
Mean number of severe exacerbations in the last
12 months 8 SD 1.881.0 3.785.5 0.175
Mean number of emergency visits in the last
12 months 8 SD 0.781.3 1.183.6 0.460
Concomitant medication, % 96.2 90.6 0.241
Systemic corticosteroids, % 66.0 39.6 0.006
LABA, % 71.7 62.3 0.302
SABA, % 73.6 83.0 0.239
Detected allergens, %d
Birch 53.3 53.1 0.979
Grass pollen 56.6 55.1 0.969
House dust mites 60.0 38.8 0.040
Cat dander 53.3 44.9 0.414
Alternaria 13.3 14.3 0.894
Cladosporium 13.3 4.1 0.108
Food 15.5 18.4 0.717
Other 37.8 34.7 0.756
Continuous data are expressed as means 8 SD (range); nominal data are given as percentages.
a 2 test (nominal data) or t test (interval data) were performed. b Percentage of predicted standard value.
c Asthma severity by the NVL. d Documented by the treating physician (skin prick test).
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 Comparison of Treatment Outcomes within and 
between Groups 
 Table 2 provides a summary of the primary outcome 
measures for within-group changes as well as between-
group differences. Overall, patients in both comparison 
groups showed substantial and significant improvements 
expressed as % reductions in most of the outcome mea-
sures.
 Notable exceptions were the lack of a significant im-
provement in total ACT score for both groups ( fig. 2 a). 
However, significant improvements were observed in 
some of the subscores in the ACT ( fig. 3 ).
 Number of Asthma Attacks and Symptoms Score 
 As shown in  figure 4 a, the proportion of patients with 
at least one severe asthma attack in the past month was 
reduced from baseline 35.9 to 17% at T2 and 18.9% at T3 
in the OT group (p = 0.028). Similarly, the mean number 
of attacks and exacerbations ( fig. 4 b) was significantly 
(p = 0.031) reduced from a mean at baseline of 4.0 (SD 
9.6) to 2.1 (5.5) at T2 and 1.1 (SD 3.0) in the whole group, 
and from 11.2 (SD 13.5) to 7.1 (SD 7.6) among those with 
at least one exacerbation. This finding is largely due to 
a substantial increase in patients who became complete-
ly free of exacerbations. At T3, 43 (81.1%) patients re-
ported no more exacerbations during the past month 
(data not shown). In the control group, a similar pattern 
emerged with a significant (p = 0.019) reduction of the 
number of patients without attacks; however, the reduc-
tion of the mean number of attacks in the total sample 
and among those with attacks was not significant (p = 
0.593). 
 There was some, though insignificant, reduction of 
symptom frequency and persistence in the past month for 
both groups. In the OT group the mean symptom score 
declined from 4.9 (SD 3.6) at baseline to 4.2 (SD 3.9) at T3 
(p = 0.151), and in the control group from 5.0 (SD 4.0) to 
4.8 (SD 3.8) at T3 (p = 0.734) (data not shown). It is, how-
ever, noteworthy that patients in the OT group versus pa-
tients in the UC group revealed a significant reduction in 
the number of patients with daily symptoms (from T1: 
84.0 to 69.2%; p = 0.042), whereas the controls did not 
(T1: 75.5%, T3: 75.5%; p = 1.00) ( fig. 2 ).
 Asthma Control According to ACT 
 The proportion of patients with ‘no control’ and ‘par-
tial control’ was reduced in the OT group (T1: 94.2%, T2: 
78.2%, T3: 81.1%), constituting a significant reduction 
Table 2.  Comparison of treatment outcomes in patients of the OT group (n = 51) and matched controls (UC, n = 53)
OT group U C group Between-
group
effect
T1–T3
changea 
T1–T2
changea 
T1–T3
within-group 
effect T1–T3
chan gea 
T1–T2
changea
T1–T3
within-group 
effect T1–T3
p
valueb
effect 
sizec
p
valueb
effect 
sizec
p valued
Number of patients with asthma attacks –55.6 –50.0 0.028 –54.5 –40.9 0.019 0.344
Mean number of asthma attacks –53.8 –72.9 0.031 0.40 –23.9 –22.2 0.592 0.09 0.100
Number of patients with daily or frequent asthma symptoms –22.5 –17.5 0.042 –5.0 0.0 1.000 0.104
Asthma control
ACT 6.5 5.9 0.265 0.18 11.1 0.6 0.886 0.04 0.801
Patients with partial/no control –14.9 –10.6 0.096 –8.9 –6.7 0.261 0.215
Impairment: never 150.0 80.0 0.019 100.0 30.8 0.289 0.795
Emergency medication: rarely/never 14.3 28.6 0.135 17.4 13.0 0.444 0.952
Short of breath: rarely/never 5.0 –15.0 0.371 0.0 –20.8 0.168 0.688
Perceived asthma control: always 500.0 300.0 0.006 157.1 57.1 0.209 0.872
Mean generic quality of life (EQ-5D) 4.0 2.3 0.543 0.14 1.8 0.6 0.839 0.01 0.733
Any problems in usual activities 0.0 –47.6 0.010 –23.8 9.5 0.598 0.006
Any pain/discomfort –35.7 –21.4 0.110 –18.8 –18.8 0.159 0.436
Ref erence group is UC controls; ratio and 95% CI estimated by a general linear model.
a Change is change in % from T1 value.
b Paired t test (interval data) or paired sample proportion test (nominal data) were performed.
c Effect size is the standardized mean difference, only indicated for continuous measures.
d Between-group effect of change T1–T3 determined by a bootstrap test for ratios. 
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from baseline to T2 (p = 0.024) and to T3 (p = 0.049). In 
contrast, the reduction in the UC group was less pro-
nounced and was insignificant (p = 0.112 and p = 0.261), 
particularly due to a worsening of control at T3 ( fig. 2 a). 
No significant improvement was observed when regard-
ing the ACT mean score for both groups ( fig. 2 b).
 This is despite the fact that, as assessed by ACT, the 
proportion of patients reporting no impairments due to 
asthma in the past 4 weeks increased significantly (p = 
0.019) in the OT group (19% at baseline to 47% at T2 and 
36% at T3). Further, the proportion of patients reporting 
being able to ‘always’ control their asthma increased from 
6 to 34% (T2) and 26% (p = 0.006). These effects were less 
pronounced (effect size: OT group 0.35 and 0.51 vs. 0.18 
and 0.24 in the UC group) and were not significant in the 
control group.
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 Emergency Medication and Treatment 
 At baseline, 20 out of 53 patients reported at least one 
emergency visit in the past month. This number was re-
duced to 4 at T2 and 9 at T3 in the OT group, which con-
stitutes a significant improvement (62%, p = 0.012), and 
from 11 at T2 to 5 at T3 in the UC group (not significant, 
p = 0.709), respectively. This is consistent with the ACT 
rating of needing ‘rarely or never reliever medication’. 
The proportion of patients increased from 40% at base-
line to 47% at T2 and 62.8 at T3 in the OT group (p = 
0.091) compared to the nonsignificant change from 24, 47 
and 37% in the UC group (p = 0.444).
 Quality of Life 
 Although patients in the OT group reported signifi-
cantly fewer reductions in their limitation of everyday ac-
tivities from T1 (41.5%) to T3 (20.8%, p = 0.0006), and in 
the UC group there was no change (38.5 at T1 and 41.5% 
at T3), we observed no significant change in the EQ-5D 
generic total score regarding quality of life. The pre- and 
post-treatment EQ-5D value in both groups approached 
very closely the level of healthy controls; thus, there was 
no room for further improvement. Neither group re-
vealed substantial changes nor were there substantial dif-
ferences between groups. 
 Concomitant Asthma Medication 
 Table  3 displays the change of concomitant asthma 
medication across T1–T3 in the OT group and in the UC 
group, respectively. Overall and for most medication 
classes, substantial and mostly significant reductions are 
apparent for the OT group, whereas changes for the con-
trol group were less pronounced. Noteworthy between-
group differences were found for long-acting beta ago-
nists (LABA; p = 0.063), anticholinergics (p = 0.065, data 
not shown), ICS (p = 0.029) and leukotriene antagonists 
(p = 0.054).
 At T1, 68.6–72.5% of all patients in the OT group were 
treated with systemic glucocorticoids, LABA and short-
acting beta agonists (SABA) (39.6–83.0% in the UC 
group). The data reveal that there was a significant reduc-
tion of all three agents in the OT group at T3. At T3, a 
further intake was necessary for 60% fewer patients than 
at T1 and 75.7% fewer patients had to continue the intake 
of LABA. The reductions were less pronounced in the UC 
group and became significant for LABA only (p  ! 0.001, 
effect size 1.14). It should be noted, however, that a sig-
nificant within-group-effect was found in the UC group 
while no significant change was detected in the OT group 
with regard to ICS. Significant between-group-effects 
from T1–T3 were found for the ICS treatment (p  ! 0.05).
 Discussion 
 The results of this naturalistic study in routine spe-
cialty care provide prospective-longitudinal evidence of 
the effects of OT in SAA patients. The strengths of this 
paper are the reliance on a representative sample of pa-
tients in respiratory care, the minimal selection effects 
and the incorporation of carefully matched controls. 
Thus, these design features could be regarded as a consid-
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erably tougher test of the effect of omalizumab than those 
in previous studies  [1, 4, 9, 10, 21] .
 What Our Data Reveal 
 Patients with SAA showed substantial improvement 
on OT in almost all the indicators considered. The effect 
size appears to be in the same range as in previous real-
life naturalistic studies  [9, 10] .
 There was also a considerable improvement in the UC 
group. Thus, both treatment groups showed significant 
improvement in most outcome measures examined. The 
improvement in the control group is not surprising, as 
these patients appear to have also received a very inten-
sive treatment, the important difference being that they 
did not receive omalizumab. 
 Consistent with earlier studies, on OT there was a sig-
nificant reduction of medication  (relevant for asthma 
control) and a substantial reduction of asthma attacks 
and exacerbations. Moreover, substantial improvements 
were found in the degree of the perceived control and per-
ceived impairment experienced by the patients in every-
day life due to their disease. 
 However, there was neither a strong nor a statistical 
overall effect in the ACT as one primary outcome mea-
sure, nor could we demonstrate a consistent improve-
ment in quality of life. Despite the finding that effect siz-
es and % improvements in all outcome measures were 
typically larger and statistically significant only in the 
OT group, our at-first-sight puzzling failure to demon-
strate a clear superiority of omalizumab in the between-
group comparison by means of the ACT score can be at-
tributed to a combination of several factors. First, the 
most prominent effect of omalizumab is a reduction in 
exacerbations, confirmed in our study. However, the 
study period of 6–8 months might have been too short to 
detect significant differences in exacerbations. Other im-
provements due to omalizumab primarily measured by 
the ACT score might be not as prominent. Second, de-
spite similar improvements in effect sizes in this study 
when compared to others, the ACT might not be respon-
sive enough for such changes. The ACT was developed 
and validated as a screening tool for asthma control state 
and not for measuring treatment effects. Alternatively, 
despite initial power calculations based on previous natu-
ralistic study findings, our study was insufficiently pow-
ered to detect significant differences in ACT scores. 
Third, and probably most important, although our SAA 
patients improved under effective treatment, they will 
rarely achieve high (controlled) ACT scores. There was 
little room for score changes in this patient population 
compared to initially severe asthma patients with an ex-
cellent response to low-dose ICS treatment (treatment 
step 2). 
 Similarly, the failure to demonstrate a significant ef-
fect in quality of life might be due to a combination of the 
fairly normal mean generic quality of life of allergic-asth-
ma patients treated in the health care system that we de-
tected and the lack of change sensitivity in this upper 
range. It should be noted that we considered the use 
of asthma-specific quality-of-life instruments, which 
turned out to not be feasible for logistical reasons. The 
AQLQ is an option to measure quality of life in patients 
with severe asthma forms and also is suitable for retest 
purposes. However, as it consists of 32 questions, each of 
Table 3.  Concomitant medication in 53 OT patients and matched controls (UC, n = 53)
OT group U C group Between-
group effect 
T1–T3
p valuec
T1 changea
T1–T2
changea
T1–T3
within-group
effect T1–T3
p valueb
T1 changea 
T1–T2
changea 
T1–T3
within-group
effect T1–T3
p valueb
SABA, % 70.6 –11.1 –25.0 0.038 62.3 –9.1 –15.2 0.255 0.991
LABA, % 72.5 –75.7 –75.7 0.000 83.0 –61.4 –59.1 0.000 0.063
Systemic glucocorticoids, % 68.6 –42.9 –60.0 0.000 39.6 –23.8 0.0 1.000 0.193
ICS, % 86.3 0.0 6.8 0.322 88.7 –10.6 –14.9 0.018 0.029
Leukotriene antagonists, % 39.2 –30.0 –20.0 0.252 22.6 –25.0 –33.3 0.209 0.054
Ref erence group is UC; ratio and 95% CI estimated by a general linear model.
a Change is change in % from T1 value.
b Paired t test (interval data) or paired sample proportion test (nominal data) were performed.
c Between-group effect of change T1–T3 determined by a bootstrap test for ratios.
 Wittchen  /Mühlig  /Klotsche  /Buhl  /
Kardos  /Ritz  /Riedel  
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which has to be answered on a 7-point scale, its feasibility 
and acceptability for follow-up assessments were found to 
be restricted because of the associated time burden. We 
therefore used a considerably shorter instrument to eval-
uate the generic quality of life at the expense of not having 
fine-graded disease-specific information that would have 
been available from the AQLQ.
 It is important to understand which factors drive the 
decision of the respiratory specialists and the not-con-
trolled SAA patients about whether or not to treat with 
omalizumab. The symptoms of allergic asthma are be-
lieved to be due to an inflammatory process, where IgE-
mediated events are thought to play a crucial role  [22, 23] . 
By almost eliminating serum free IgE levels, omalizumab 
has been shown to provide a specific method to treat this 
condition effectively, with results that are superior to 
standard treatments in SAA patients with inadequate 
disease control  [24, 25] .
 One has to keep in mind that the selection of patients 
in both groups was based on an epidemiological sam-
pling strategy (as described in  [12] ) and a comprehensive 
clinical patient assessment by the treating physician. 
Thus, the selection of patients with a prospective OT in 
our study was based entirely on the clinician’s appraisal 
and the respective information coded in the standardized 
assessment forms. As previously reported, we found no 
indications for selection bias in the preceding stage II 
component of our study program  [12] (from where stage 
III patients were taken), and – with one exception (sys-
temic corticosteroids) – there were no noteworthy differ-
ences between the 2 patient groups (with and without OT 
treatment). However, given the complete reliance on the 
data supplied by the treating physicians and the lack of 
independent information, more subtle selection effects 
cannot be entirely excluded. Another possible limitation 
in the data might be caused by the relatively short obser-
vation period of 6 months, which was chosen for eco-
nomic and logistical reasons (study budget and addition-
al burden for the participating physicians and patients).
 In the noninterventional study, one can speculate why 
the matched control patients were not treated. Several 
reasons are possible: The IgE levels in the control group 
were higher, thus more patients could have exceeded the 
maximum approved dose (375 mg every 2 weeks at the 
time of the study; today doses as high as 600 mg every 2 
weeks are even approved). The systemic steroid dose was 
significantly higher in the OT patients. It is likely that the 
respiratory specialists targeted such patients expecting a 
reduction in the systemic steroid dose. Omalizumab in 
Germany is fully reimbursed and financial or social as-
pects do not play any role in its prescription, thus making 
the 2 groups even more comparable.
 To conclude, the substantial beneficial effects of omali-
zumab, similar to those observed in controlled trials as 
well as in post-marketing surveillance studies, were con-
firmed, particularly with regard to the reduction of asthma 
exacerbations and attacks, the persistence of asthma symp-
toms, asthma control and the reduction of concomitant 
asthma medications. The failure to show a substantial and 
consistent improvement in the generic and some of the 
asthma-related quality-of-life measures may be attributed 
to a lack of sensitivity of the instrument used. It should also 
be noted that, as sap-NEEDs was a naturalistic study con-
ducted in the daily routine care of pulmonary specialists, 
we did not implement comprehensive instruments to as-
sess therapy response as is customary in randomized con-
trolled trials. However, our results indicate a substantial 
improvement in the condition of patients and it is unlikely 
that physicians would continue a therapy strategy that 
turns out to be ineffective. Overall, this study provides a 
tougher test than previous investigation by comparing the 
omalizumab performance against adequately managed 
standard treatment, thus adding further evidence to the 
considerable benefit of this new treatment option. 
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